EU panel backs approval of Celgene's Revlimid for MDS

04/30/2013 | MDSBeacon.com

The European Medicines Agency's Committee for Medicinal Products for Human Use recommended the approval of Celgene's Revlimid, or lenalidomide, to treat certain patients with myelodysplastic syndromes. EMA could release its approval decision within two to three months. Revlimid is already sold as a treatment for multiple myeloma in Europe and the U.S.

View Full Article in:

MDSBeacon.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ